UBS Group Begins Coverage on Solventum (NYSE:SOLV)

Key Points

• UBS Group has initiated coverage on Solventum (NYSE:SOLV) with a "neutral" rating and a price target of $77.00, suggesting a potential upside of 3.28% from its previous close.
• Analyst ratings for Solventum vary, with one Strong Buy, four Buy, six Hold, and one Sell, leading to a current consensus rating of "Hold" and a target price of $84.60.
• Solventum reported $1.69 earnings per share for the last quarter, exceeding analysts' expectations, and has projected FY 2025 earnings guidance of $5.800-5.950 EPS.

Equities researchers at UBS Group initiated coverage on shares of Solventum (NYSE:SOLV - Get Free Report) in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The firm set a "neutral" rating and a $77.00 price target on the stock. UBS Group's price target suggests a potential upside of 3.28% from the company's previous close.

A number of other equities research analysts have also weighed in on SOLV. Wall Street Zen lowered shares of Solventum from a "strong-buy" rating to a "buy" rating in a report on Tuesday, September 9th. Piper Sandler reaffirmed an "overweight" rating and issued a $94.00 price target (up from $87.00) on shares of Solventum in a report on Friday, August 8th. Argus raised shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 price target on the stock in a report on Tuesday, July 1st. Wells Fargo & Company upped their price target on shares of Solventum from $79.00 to $82.00 and gave the company an "equal weight" rating in a report on Monday, September 15th. Finally, KeyCorp initiated coverage on shares of Solventum in a report on Friday, June 6th. They issued a "sector weight" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $84.60.

Solventum Price Performance

Shares of SOLV opened at $74.56 on Wednesday. The firm has a market capitalization of $12.93 billion, a PE ratio of 34.52, a price-to-earnings-growth ratio of 2.97 and a beta of 0.50. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. Solventum has a 1-year low of $60.70 and a 1-year high of $85.92. The company's fifty day moving average price is $72.82 and its 200-day moving average price is $72.22.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating analysts' consensus estimates of $1.45 by $0.24. The firm had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities research analysts predict that Solventum will post 6.58 EPS for the current year.

Institutional Trading of Solventum

A number of hedge funds have recently bought and sold shares of SOLV. Independent Franchise Partners LLP raised its holdings in Solventum by 74.2% in the 2nd quarter. Independent Franchise Partners LLP now owns 10,141,066 shares of the company's stock valued at $769,098,000 after acquiring an additional 4,320,342 shares during the last quarter. Norges Bank acquired a new stake in Solventum in the 2nd quarter valued at about $140,495,000. Boston Partners raised its holdings in Solventum by 101.3% in the 1st quarter. Boston Partners now owns 3,361,973 shares of the company's stock valued at $255,554,000 after acquiring an additional 1,691,565 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Solventum by 738.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 566,623 shares of the company's stock valued at $43,086,000 after acquiring an additional 499,031 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in Solventum in the 1st quarter valued at about $35,375,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.